Evaluation of the Clinical Utility of Circulating Biomarkers in Advanced Thyroid Carcinomas

Recruiting now

Conditions studied: Thyroid Carcinoma

In brief

The study is aimed at all adult patients diagnosed with advanced thyroid carcinomas and well-differentiated thyroid carcinomas (DTC) iodine-refractory, well-differentiated iodine-refractory thyroid (RAI-R DTC) metastatic carcinomas that are candidates for systemic therapy. By simple blood sampling and analysis on peripheral blood of circulating DNA (ccf-DNA), circulating RNA (ccf-RNA), and counting and analysis of circulating tumor cells through the use of liquid biopsy, molecular profiling corresponding to those obtained by genomic sequencing on tumor tissue can be arrived at, depending on optimal therapeutic choices

Key facts

Study ID: NCT06863805
Run by: IRCCS Azienda Ospedaliero-Universitaria di Bologna
People needed: 10
Starts: 2022-12-15
Expected to finish: 2027-12-31
Last updated by the study team: 2025-03-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Signed written informed consent,
Adult (≥18 years) male or female patients
Histologic diagnosis of advanced thyroid carcinoma confirmed at centralized review,
well-differentiated thyroid carcinomas, medullary thyroid carcinomas, anaplastic thyroid carcinomas, advanced, candidates for initiation of systemic medical therapy,
Availability of biomolecular profiling performed by multigenic NGS panel on tumor tissue,
Measurable disease by conventional imaging adopted in clinical practice (total body CT with mdc, CT-PET with FDG or F-DOPA).

You may not qualify if…

Patients already receiving previous lines of systemic therapy,
Patients not eligible for systemic therapy.

Where it is running

IRCCS Azienda Ospedaliero universitaria Bologna — Bologna, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.